Forendo Pharma

long shot miss basketball hoop fail shoot
Biotech

Organon axes 'biggest potential opportunity' after trial fail

An endometriosis drug candidate Organon hailed as perhaps its “biggest potential opportunity” has flunked a phase 2 trial.
Nick Paul Taylor Jul 2, 2025 8:43am
handshake

Organon buys Forendo in 3rd deal since spinning out of Merck

Nov 11, 2021 8:40am